Rosiglitazone
( DrugBank: Rosiglitazone / KEGG DRUG: Rosiglitazone maleate, Rosiglitazone )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 77 | Growth hormone secreting pituitary adenoma | 1 |
| 97 | Ulcerative colitis | 3 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 222 | Primary nephrotic syndrome | 1 |
77. Growth hormone secreting pituitary adenoma
Clinical trials : 351 / Drugs : 241 - (DrugBank : 28) / Drug target genes : 26 - Drug target pathways : 87
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
97. Ulcerative colitis
Clinical trials : 3,305 / Drugs : 1,646 - (DrugBank : 318) / Drug target genes : 165 - Drug target pathways : 220
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
222. Primary nephrotic syndrome
Clinical trials : 382 / Drugs : 278 - (DrugBank : 98) / Drug target genes : 73 - Drug target pathways : 197
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
